Document is current
Any future updates will be listed below
-
Authors
St-Pierre, Frederique https://orcid.org/0000-0002-8495-8579
Bhatta, Subodh https://orcid.org/0000-0003-3804-5370
Doukas, Peter G.
Jenkin, Madeline https://orcid.org/0009-0003-2920-4875
Annunzio, Kaitlin
Rojek, Alexandra E.
Gibson, Alyssa
Tiger, Yun Kyoung https://orcid.org/0000-0002-8745-0906
McCall, Brittany
Alhamad, Khaled
Hansen, Alec
Alderuccio, Juan P. https://orcid.org/0000-0002-2690-3377
Adewale, Olutobi
Patel, Keem
Trabolsi, Asaad https://orcid.org/0000-0002-2479-1797
Lossos, Izidore S. https://orcid.org/0000-0002-9346-9013
Fitzgerald, Lindsey
Ollila, Thomas A. https://orcid.org/0000-0003-0102-6491
Matasar, Matthew J.
Kline, Justin
Karmali, Reem https://orcid.org/0000-0003-0984-4376
Epperla, Narendranath https://orcid.org/0000-0002-8216-3457
- License Information
-
More Information
Article History
Received: 23 December 2024
Revised: 23 May 2025
Accepted: 12 June 2025
First Online: 21 June 2025
Competing interests
: NE: Research Funding (institution) from Beigene, ADC Therapeutics, Lilly, Incyte, and Ipsen. Advisory board for Genentech, CRISPR Therapeutics and Ipsen. RK: Advisory Board: BMS, Genentech/Roche, Abbvie, GenMab; Speakers Bureau: BeiGene, AstraZeneca, BMS. JPA: Research support: ADC Therapeutics, Genmab, AbbVie, and BeiGene. Consultancy: ADC Therapeutics, Genentech, AbbVie, Lilly, Novartis, and Regeneron. TAO: Ad board for ADC therapeutics, Honoraria and research support for ONO pharmaceuticals.
: Permission granted by Wiley to reproduce Fig. from: .
